Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Termination
Details : MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
May 04, 2022
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by I...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $230.0 million
April 10, 2021
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Details : In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
December 08, 2020
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020
Details : Topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer will be published at the ASCO 2020 Annual Conference.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Theradex
Deal Size : Inapplicable
Deal Type : Inapplicable
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 18, 2019
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Theradex
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 26, 2019
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pharm-Olam
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 16, 2015
Lead Product(s) : L-DOS47
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pharm-Olam
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 05, 2014